400
Participants
Start Date
November 30, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
TNFi (Tumor Necrosis Factor inhibitor) medication
"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"
Abatacept
"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"
Tocilizumab
"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"
Tofacitinib
"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"
Lead Sponsor
Patient-Centered Outcomes Research Institute
OTHER
Duke University
OTHER